NEW PRESIDENT AND CEO FOR BIOHIT OYJ

BIOHIT OYJ STOCK EXCHANGE RELEASE ON 10 JUNE 2010 AT 1:40 PM                    

NEW PRESIDENT AND CEO FOR BIOHIT OYJ                                            

Professor Osmo Suovaniemi, 66, founder of Biohit, today announced his           
resignation from his position as President and CEO of the company.              

As of 10 June 2010, his duties will be taken over by Jussi Heiniö, 48, LLM. Mr  
Heiniö has been with Biohit since 1997 and for the last six years he has served 
as the company's VP of Administration and Legal Affairs, and as Executive Vice 
President. Additionally, he has acted as Chairman of the Board of all           
subsidiaries and has been actively involved in the development of their local   
business activities, particularly in emerging markets.                          

"Jussi Heiniö is the natural choice as Osmo Suovaniemi's successor. He knows the
company, its markets and challenges, so we are confident that, together with our
expert staff, he will be able to steer the company towards success", affirms    
Reijo Luostarinen, Chairman of the Board of Biohit Oyj.                         

"Biohit has grown into a global player with employees in 11 countries on three  
continents", Heiniö comments. "It is my goal to develop the company's business  
in a truly international direction, by utilising the Group's own resources and  
large network of subsidiaries. We offer unique innovations, first-rate products 
and highly skilled personnel. Osmo Suovaniemi has made Biohit a success with
his inventions and fearless approach, and I am very excited about having the
opportunity to continue this story." 

Osmo Suovaniemi is not leaving the company. He continues to take active part in 
the development of innovations in his future roles as Chairman of the Board of  
Scientific Advisors. In addition, he will continue as a member of Biohit Oyj's  
Board of Directors.                                                             

JUKKA ANT-WUORINEN NAMED NEW DEPUTY CHAIRMAN OF THE BOARD                       

In its meeting of today, the Board of Directors of Biohit Oyj named Jukka       
Ant-Wuorinen, B.Sc. (Econ.) deputy chairman of the Board. Professor Reijo       
Luostarinen continues as chairman.                                              

Board of Directors of Biohit Oyj                                                



Further information:                                                            
Osmo Suovaniemi, M.D., Ph.D., Professor                                         
Tel: +358-9-773 861                                                             
GSM: +358-40-745 5605                                                           
Email: osmo.suovaniemi@biohit.com                                               

Pictures:
Josefin Hoviniemi
Tel: +358-09-7738 6363
Email: josefin.hoviniemi@biohit.com

Distribution:                                                                   
NASDAQ OMX Helsinki Oy                                                          
Central storage facility (www.oam.fi)                                           
Press                                                                           
www.biohit.com                                                                  


About Biohit Oyj                                                                

Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on   
the global market. Biohit's operations are based on a goal-oriented and         
long-term innovation and patenting strategy.                                    
                                                                                
Biohit works with scientific communities to produce new technologies, products  
and services based on research results and innovations that can be used to      
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of  
the gastrointestinal tract.                                                     

Biohit has two business segments: liquid handling and diagnostics. Liquid       
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions, 
healthcare and industrial laboratories.                                         

The diagnostics business comprises products and analysis systems for the early  
diagnosis of gastrointestinal diseases, such as the blood-sample based          
GastroPanel examinations for the diagnosis of stomach illnesses and associated  
risks, quick tests for the diagnosis of lactose intolerance and H. pylori       
infection in connection with gastroscopy, and the ColonView examination for the 
early detection of intestinal bleeding that indicates a risk of colorectal      
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic    
stomachs.                                                                       

The Biohit Group employs around 390 people. The company is headquartered in     
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,     
India, China, Japan and the USA, as well as a representative office in          
Singapore. Additionally, Biohit's products are sold by approximately 450        
distributors in 70 countries.                                                   

Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small         
cap/Healthcare since 1999.                                                      

Read more at www.biohit.com